Top Markets
Coin of the day
Medigen Biotechnology Corp. Medigen Biotechnology Corp.

Medigen Biotechnology Corp.

3176
株式のランク #19061
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated... Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
株価
$1.27
時価総額
$176.31M
変化(1日)
5.57%
変化(1年)
29.36%
TW
取引 Medigen Biotechnology Corp. (3176)

カテゴリー

Medigen Biotechnology Corp.(3176)の配当利回りの履歴
Medigen Biotechnology Corp.(銘柄コード: 3176)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Medigen Biotechnology Corp.(3176)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)